|Request a Quote or Start an on-line Chat
24T ELISA Kit Trial Size (Only USD$150/ kit)
|Intra-assay Precision (Precision within an assay): CV%<8%
|Three samples of known concentration were tested twenty times on one plate to assess.
|Inter-assay Precision (Precision between assays): CV%<10%
|Three samples of known concentration were tested in twenty assays to assess.
|To assess the linearity of the assay, samples were spiked with high concentrations of human PIN1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
|The recovery of human PIN1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
|Average % Recovery
|EDTA plasma (n=4)
|These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
This human PIN1 ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human PIN1 in multiple samples, including serum, plasma, urine, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the PIN1 levels in the sample and is measured at 450 nm through a microplate reader.
PIN1 specifically binds and isomerizes the phosphorylated serine/threonine–proline motif, which leads to the alteration of protein structure, function, and stability. The altered structure and function of these phosphorylated proteins regulated by PIN1 are closely related to cancer development. PIN1 participates in cellular processes such as the cell cycle, the folding of newly synthesized proteins, responses to DNA damage and stress, and immune responses. PIN1 is highly expressed in human cancers, including prostate cancer, breast cancer, and oral squamous carcinomas. PIN1 drives tumor progression and is negatively associated with clinical outcomes in patients with cancer.
There are currently no reviews for this product.